000179643 001__ 179643
000179643 005__ 20240229145550.0
000179643 0247_ $$2doi$$a10.3390/cancers14081981
000179643 0247_ $$2pmid$$apmid:35454886
000179643 0247_ $$2altmetric$$aaltmetric:127173868
000179643 037__ $$aDKFZ-2022-00817
000179643 041__ $$aEnglish
000179643 082__ $$a610
000179643 1001_ $$aLin, Hui-Yi$$b0
000179643 245__ $$aIntake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status.
000179643 260__ $$aBasel$$bMDPI$$c2022
000179643 3367_ $$2DRIVER$$aarticle
000179643 3367_ $$2DataCite$$aOutput Types/Journal article
000179643 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1650965356_16148
000179643 3367_ $$2BibTeX$$aARTICLE
000179643 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179643 3367_ $$00$$2EndNote$$aJournal Article
000179643 520__ $$aPrevious studies have shown that different alcoholic beverage types impact prostate cancer (PCa) clinical outcomes differently. However, intake patterns of specific alcoholic beverages for PCa status are understudied. The study's objective is to evaluate intake patterns of total alcohol and the three types of beverage (beer, wine, and spirits) by the PCa risk and aggressiveness status.This is a cross-sectional study using 10,029 men (4676 non-PCa men and 5353 PCa patients) with European ancestry from the PCa consortium. Associations between PCa status and alcohol intake patterns (infrequent, light/moderate, and heavy) were tested using multinomial logistic regressions.Intake frequency patterns of total alcohol were similar for non-PCa men and PCa patients after adjusting for demographic and other factors. However, PCa patients were more likely to drink wine (light/moderate, OR = 1.11, p = 0.018) and spirits (light/moderate, OR = 1.14, p = 0.003; and heavy, OR = 1.34, p = 0.04) than non-PCa men. Patients with aggressive PCa drank more beer than patients with non-aggressive PCa (heavy, OR = 1.48, p = 0.013). Interestingly, heavy wine intake was inversely associated with PCa aggressiveness (OR = 0.56, p = 0.009).The intake patterns of some alcoholic beverage types differed by PCa status. Our findings can provide valuable information for developing custom alcohol interventions for PCa patients.
000179643 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179643 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179643 650_7 $$2Other$$aaggressiveness
000179643 650_7 $$2Other$$aalcohol
000179643 650_7 $$2Other$$abeverage
000179643 650_7 $$2Other$$aprostate cancer
000179643 7001_ $$00000-0001-6266-9891$$aTseng, Tung-Sung$$b1
000179643 7001_ $$aWang, Xinnan$$b2
000179643 7001_ $$aFang, Zhide$$b3
000179643 7001_ $$aZea, Arnold H$$b4
000179643 7001_ $$00000-0002-9364-8572$$aWang, Liang$$b5
000179643 7001_ $$aPow-Sang, Julio$$b6
000179643 7001_ $$aTangen, Catherine M$$b7
000179643 7001_ $$aGoodman, Phyllis J$$b8
000179643 7001_ $$aWolk, Alicja$$b9
000179643 7001_ $$aHåkansson, Niclas$$b10
000179643 7001_ $$aKogevinas, Manolis$$b11
000179643 7001_ $$aLlorca, Javier$$b12
000179643 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b13$$udkfz
000179643 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b14$$udkfz
000179643 7001_ $$aCastelao, Jose Esteban$$b15
000179643 7001_ $$aGago-Dominguez, Manuela$$b16
000179643 7001_ $$aGamulin, Marija$$b17
000179643 7001_ $$00000-0003-4496-244X$$aLessel, Davor$$b18
000179643 7001_ $$aClaessens, Frank$$b19
000179643 7001_ $$00000-0003-3195-9890$$aJoniau, Steven$$b20
000179643 7001_ $$aThe Practical Consortium$$b21
000179643 7001_ $$aPark, Jong Y$$b22
000179643 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14081981$$gVol. 14, no. 8, p. 1981 -$$n8$$p1981$$tCancers$$v14$$x2072-6694$$y2022
000179643 909CO $$ooai:inrepo02.dkfz.de:179643$$pVDB
000179643 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000179643 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000179643 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179643 9141_ $$y2022
000179643 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000179643 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000179643 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000179643 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000179643 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000179643 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000179643 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000179643 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000179643 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000179643 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000179643 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000179643 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179643 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000179643 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000179643 980__ $$ajournal
000179643 980__ $$aVDB
000179643 980__ $$aI:(DE-He78)C070-20160331
000179643 980__ $$aI:(DE-He78)C120-20160331
000179643 980__ $$aI:(DE-He78)HD01-20160331
000179643 980__ $$aUNRESTRICTED